149 related articles for article (PubMed ID: 13677382)
21. Effect of renal maturation on the clearance of technetium-99m mercaptoacetyltriglycine.
Lythgoe MF; Gordon I; Anderson PJ
Eur J Nucl Med; 1994 Dec; 21(12):1333-7. PubMed ID: 7875172
[TBL] [Abstract][Full Text] [Related]
22. 99mTc-mercaptoacetyltriglycine camera-based measurement of renal clearance: should the result be normalized for body surface area?
Klingensmith WC
J Nucl Med Technol; 2013 Dec; 41(4):279-82. PubMed ID: 24167023
[TBL] [Abstract][Full Text] [Related]
23. Radiopharmacokinetics, renal clearance and dosimetry of 99mTc-MAG3.
Arteaga de Murphy C; Molina-Trinidad E; Meléndez-Alafort L; Ferro-Flores G; Reyes-Herrera L; Sepúlveda-Méndez J; Sandoval-Guzmán B; Hoyo-Vadillo C
Arch Med Res; 1999; 30(1):49-54. PubMed ID: 10071425
[TBL] [Abstract][Full Text] [Related]
24. Factors affecting the hepatobiliary excretion of 99mTc-MAG3: its clinical significance in routine renography.
Arroyo AJ; Semaan HB; Minkus KD; Patel YP
J Nucl Med Technol; 2003 Mar; 31(1):18-20. PubMed ID: 12624122
[TBL] [Abstract][Full Text] [Related]
25. Estimation of technetium-99m-MAG3 plasma clearance in adults from one or two blood samples.
Russell CD; Taylor A; Eshima D
J Nucl Med; 1989 Dec; 30(12):1955-9. PubMed ID: 2531219
[TBL] [Abstract][Full Text] [Related]
26. Effect of warm ischemia on renal function during partial nephrectomy: assessment with new 99mTc-mercaptoacetyltriglycine scintigraphy parameter.
Funahashi Y; Hattori R; Yamamoto T; Sassa N; Fujita T; Gotoh M
Urology; 2012 Jan; 79(1):160-4. PubMed ID: 22070892
[TBL] [Abstract][Full Text] [Related]
27. A Bayesian 3-compartment model for 99mTc-MAG3 clearance.
Russell CD
J Nucl Med; 2003 Aug; 44(8):1357-61. PubMed ID: 12902428
[TBL] [Abstract][Full Text] [Related]
28. [Unilateral effective renal plasma flow measurement using one-compartment analysis of 99mTc-MAG3 and gamma-camera renography].
Oriuchi N; Tokunaga M; Suzuki H; Inoue T; Ohnishi Y; Inoue T; Endo K
Nihon Igaku Hoshasen Gakkai Zasshi; 1995 Sep; 55(11):757-62. PubMed ID: 8532508
[TBL] [Abstract][Full Text] [Related]
29. Improved renal clearance and tumor targeting of 99mTc-labeled anti-Tac monoclonal antibody Fab by chemical modifications.
Kim MK; Jeong HJ; Kao CH; Yao Z; Paik DS; Pie JE; Kobayashi H; Waldmann TA; Carrasquillo JA; Paik CH
Nucl Med Biol; 2002 Feb; 29(2):139-46. PubMed ID: 11823118
[TBL] [Abstract][Full Text] [Related]
30. Assessment of renal function in mice with unilateral ureteral obstruction using 99mTc-MAG3 dynamic scintigraphy.
Tantawy MN; Jiang R; Wang F; Takahashi K; Peterson TE; Zemel D; Hao CM; Fujita H; Harris RC; Quarles CC; Takahashi T
BMC Nephrol; 2012 Dec; 13():168. PubMed ID: 23228112
[TBL] [Abstract][Full Text] [Related]
31. Comparison of camera-based 99mTc-MAG3 and 24-hour creatinine clearances for evaluation of kidney function.
Esteves FP; Halkar RK; Issa MM; Grant S; Taylor A
AJR Am J Roentgenol; 2006 Sep; 187(3):W316-9. PubMed ID: 16928911
[TBL] [Abstract][Full Text] [Related]
32. Quantification of renal function with a count-based gamma camera method using technetium-99m-MAG3 in children.
Itoh K; Nonomura K; Yamashita T; Kanegae K; Murakumo M; Koyanagi T; Furudate M
J Nucl Med; 1996 Jan; 37(1):71-5. PubMed ID: 8544005
[TBL] [Abstract][Full Text] [Related]
33. Estimation of technetium-99m-MAG3 renal clearance in children: two gamma camera techniques compared with multiple plasma samples.
Gordon I; Anderson PJ; Orton M; Evans K
J Nucl Med; 1991 Sep; 32(9):1704-8. PubMed ID: 1831838
[TBL] [Abstract][Full Text] [Related]
34. Background correction in estimating initial renal uptake. Comparison between Tc-99m MAG3 and Tc-99m DTPA.
Inoue Y; Machida K; Honda N; Takahashi T; Mamiya T
Clin Nucl Med; 1994 Dec; 19(12):1049-54. PubMed ID: 7874800
[TBL] [Abstract][Full Text] [Related]
35. Background subtraction in technetium-99m-MAG3 renography.
Taylor A; Thakore K; Folks R; Halkar R; Manatunga A
J Nucl Med; 1997 Jan; 38(1):74-9. PubMed ID: 8998155
[TBL] [Abstract][Full Text] [Related]
36. Technetium 99m mercaptoacetyltriglycine gamma camera clearance calculations: methodological problems.
Tondeur M; Piepsz A; Dobbeleir A; Ham H
Eur J Nucl Med; 1991; 18(2):83-6. PubMed ID: 1828421
[TBL] [Abstract][Full Text] [Related]
37. 99mTc-MAG3: review of pharmacokinetics, clinical application to renal diseases and quantification of renal function.
Itoh K
Ann Nucl Med; 2001 Jun; 15(3):179-90. PubMed ID: 11545186
[TBL] [Abstract][Full Text] [Related]
38. Relative 99mTc-MAG3 renal uptake: reproducibility and accuracy.
Piepsz A; Tondeur M; Ham H
J Nucl Med; 1999 Jun; 40(6):972-6. PubMed ID: 10452313
[TBL] [Abstract][Full Text] [Related]
39. Clinical evaluation of technetium-99m-L,L-ethylenedicysteine in patients with chronic renal failure.
Prvulovich EM; Bomanji JB; Waddington WA; Rudrasingham P; Verbruggen AM; Ell PJ
J Nucl Med; 1997 May; 38(5):809-14. PubMed ID: 9170451
[TBL] [Abstract][Full Text] [Related]
40. A 7% decrease in the differential renal uptake of MAG3 implies a loss in renal function.
Taylor A; Manatunga A; Halkar R; Issa MM; Shenvi NV
Urology; 2010 Dec; 76(6):1512-6. PubMed ID: 20708778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
